NDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Humorsol (demecarium bromide) is an ophthalmic solution approved in 1959 for glaucoma and accommodative esotropia. It is a cholinesterase inhibitor that increases aqueous humor outflow by enhancing parasympathomimetic activity at the eye. This legacy small-molecule addresses intraocular pressure reduction and ocular muscle dysfunction.
LOE Approaching
Product is in late maturity with moderate competitive pressure (30); expect declining sales and small, focused commercial team managing legacy business.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Humorsol offers limited career growth potential given zero linked job openings and LOE-approaching lifecycle. Professionals assigned to this product typically manage legacy operations, cost reduction, and customer retention rather than market expansion.
Brand ManagerField Sales Representative
Worked on HUMORSOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.